Core Viewpoint - Zhejiang Haisheng Medical Equipment Co., Ltd. (stock code: 920166.BJ) was listed on the Beijing Stock Exchange, closing at 34.49 yuan with a significant increase of 172.86% on the first day of trading, indicating strong market interest and investor confidence in the company’s growth potential [1]. Company Overview - Haisheng Medical is a global provider of anesthesia and monitoring medical devices, focusing on the research, production, and sales of these products, which are widely used in various clinical settings such as anesthesia, ICU, and emergency departments [1]. - The company is controlled by Huang Haisheng and Wu Xiaoye, who collectively hold 54.92% of the shares, establishing them as the actual controllers of the company [1]. Financial Information - The company raised a total of 142.76 million yuan in its public offering, with a net amount of 113.44 million yuan after expenses, which was 25.70 million yuan less than initially planned [3]. - The financial performance from 2022 to mid-2025 shows a steady increase in revenue, with figures of 26.77 million yuan, 30.59 million yuan, 30.37 million yuan, and 15.56 million yuan for the respective periods [5]. - Net profit attributable to the parent company for the same periods was 7.01 million yuan, 7.80 million yuan, 7.09 million yuan, and 3.55 million yuan, indicating a relatively stable profit margin [5]. Project Funding and Allocation - The funds raised will be allocated to three main projects: upgrading and expanding production of anesthesia and emergency medical devices (24.84 million yuan), establishing a research and testing center (17.67 million yuan), and building a marketing service base (5.76 million yuan) [4]. - The total estimated investment for these projects is 48.27 million yuan, with the planned use of raised funds amounting to 37.04 million yuan [4]. Market and Policy Considerations - The company is subject to industry policies such as volume-based procurement and the "two-invoice system," which may impact its operational stability and performance [2]. - The company is expected to address these policy impacts and outline its strategies in future disclosures [2].

Core Points - Beijing Stock Exchange will hold its 29th review meeting on November 7, 2025, to discuss the fundraising proposal from Zhejiang Haisheng Medical Equipment Co., Ltd. [1] - Haisheng Medical plans to raise a total of 370.4254 million yuan for upgrading and expanding its anesthetic monitoring emergency medical equipment, establishing a research and testing center, and building a marketing service base [1] Project Summaries - **Anesthetic Monitoring Emergency Medical Equipment Upgrade and Automation Project** - Total investment: 248.432 million yuan - Funds raised: 173.9024 million yuan - Project status: Approved [2] - Environmental assessment: Approved (Document No. 2023) 7 [2] - **Research and Testing Center Project** - Total investment: 176.7181 million yuan - Funds raised: 138.973 million yuan - Project status: Approved [2] - Environmental assessment: Not subject to environmental assessment management [2] - **Marketing Service Base Construction Project** - Total investment: 57.55 million yuan - Funds raised: 57.55 million yuan - Project status: Approved [2] - Environmental assessment: Not subject to environmental assessment management [2] - **Total Summary** - Combined total investment: 482.7001 million yuan - Total funds raised: 370.4254 million yuan [2] Ownership Structure - Huang Haisheng directly holds 47.11% of the company's shares, making him the controlling shareholder [2] - Huang Haisheng and Wu Xiaoye, a married couple, collectively control 54.92% of the company's shares [2] - Huang Haisheng serves as the chairman and general manager, while Wu Xiaoye is the executive partner of Lixin Investment [2]

随着盈利能力连续4年下滑，海圣医疗现金流情况亦不容乐观。2022年至2025年一季度，该公司现金及现金等价物仅在2023年实现净流入，其余各期均呈 净流出态势。 作为全国麻醉和监护类医用耗材领域的头部企业，海圣医疗的历史沿革中曾短暂出现过2名机构投资者。 近日，浙江海圣医疗器械股份有限公司（以下简称"海圣医疗"）完成北交所第一轮审核问询函的回复。该公司此次IPO拟募资3.70亿元，计划用于麻醉监 护急救系列医疗器械升级扩产及自动化项目、研发检测中心项目、营销服务基地建设项目。 | 11 The See Fry 1 HH MITY IV Labert For 已受理 | 已问询 | 上市委会议 | 提交注册 | 注册结果 | | --- | --- | --- | --- | --- | | 2025-05-29 | 2025-06-27 | | | | | 代码 | 873794 | 简称 | 海圣医疗 | | --- | --- | --- | --- | | 公司全称 | 浙江海圣医疗器械股份有限公司 | 受理日期 | 2025-05-29 | | 审核状态 | 已问询 | 更新日期 | 2025-08- ...

浙江海胜医疗器械股份有限公司本次发行所募集资金主要投资以下项目一麻醉监护急救系列医疗器械升级扩产及自动化项目二研发检测中心项目三营销服务基地建设项目如果您想要了解关于浙江海胜医疗器械股份有限公司向不特定合格投资者公开发行股票 并在北交所上市网上录演的更多内容可以登陆全景网以及全景录演接下来让我们一起来认识一下参加本次录演的各位嘉宾他们分别是浙江海生医疗器械股份有限公司董事长总经理黄海生先生浙江海生医疗器械股份有限公司董事副总经理黄伟先生 浙江海胜医疗器械股份有限公司董事会秘书殷明先生浙江海胜医疗器械股份有限公司财务总监李建成先生接下来再来介绍来自保健机构的嘉宾他们分别是中信证券股份有限公司投资银行管理委员会投资银行华东一部总监保健代表人董超先生 中信证券股份有限公司投资银行管理委员会投资银行华东一部高级经理保健代表人蔡斌先生欢迎各位嘉宾的光临首先我们要有请浙江海生医疗器械股份有限公司董事长总经理黄海生先生做推介这次有请 尊敬的各位嘉宾各位投资者各位网友大家好欢迎来到全景杭州路演中心浙江海胜医疗器械股份有限公司向不特定合格投资者公开发行股票并在北交所上市网上路演现在开始本次路演由深圳市全景网络有限公司主办感谢您 ...